A Mechanically Resilient Soft Hydrogel Improves Drug Delivery for Treating Post-Traumatic Osteoarthritis in Physically Active Joints.

Intra-articular delivery of disease-modifying osteoarthritis drugs (DMOADs) is likely to be most effective in early post-traumatic osteoarthritis (PTOA) when symptoms are minimal and patients are physically active. DMOAD delivery systems therefore must withstand repeated mechanical loading without affecting the drug release kinetics. Although soft materials are preferred for DMOAD delivery, mechanical loading can compromise their structural integrity and disrupt drug release.

Sustained release resolvin D1 liposomes are effective in the treatment of osteoarthritis in obese mice.

Osteoarthritis (OA) is the most common joint disorder and currently affects >500 million patients worldwide, with ~60% of them also suffering from obesity. There is no drug approved for human use that changes the course of OA progression. OA is one of the most common comorbidities of obesity, and obesity-related OA (ObOA) is a serious health concern because it shows heightened severity of tissue damage and also predominantly affects the working population.

Wearable and implantable devices for drug delivery: Applications and challenges.

Poor adherence to drug dosing schedule is responsible for ∼50% of hospitalization cases. Most patients fail to adhere to a strict dosing schedule due to invasive drug administration, off-target toxicities, or medical conditions like dementia. The emerging concept of wearable devices (WDs), implantable devices (IDs) and combined wearable and implantable devices (WIDs) for drug delivery has created new opportunities for treating patients with chronic diseases needing repeated and long-term medical attention like diabetes, ocular disorders, cancer, wound healing, cardiovascular diseases, and contraception.

Immunomodulatory nanosystems for treating inflammatory diseases.

Inflammatory disease (ID) is an umbrella term encompassing all illnesses involving chronic inflammation as the central manifestation of pathogenesis. These include, inflammatory bowel diseases, hepatitis, pulmonary disorders, atherosclerosis, myocardial infarction, pancreatitis, arthritis, periodontitis, psoriasis. The IDs create a severe burden on healthcare and significantly impact the global socio-economic balance.

Progressive systemic sclerosis (scleroderma), carcinoma breast and valvular heart disease: an unusual combination.

Systemic sclerosis is a multi system disorder characterised by fibrosis of skin and internal organs. There are reports of relation between cancer and polymyositis/dermatomyositis, but no overall association with systemic sclerosis. Reports of the coexistence of cancer and systemic sclerosis, however, emphasise a close temporal relation in their occurrence.